1. Home
  2. RNTX vs OPAD Comparison

RNTX vs OPAD Comparison

Compare RNTX & OPAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.70

Market Cap

42.9M

Sector

Health Care

ML Signal

HOLD

OPAD

Offerpad Solutions Inc.

HOLD

Current Price

$0.88

Market Cap

35.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNTX
OPAD
Founded
2001
2015
Country
United States
United States
Employees
10
140
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
42.9M
35.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RNTX
OPAD
Price
$1.70
$0.88
Analyst Decision
Buy
Buy
Analyst Count
2
4
Target Price
$10.00
$1.83
AVG Volume (30 Days)
118.7K
668.9K
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$32.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$0.57
52 Week High
$2.22
$6.35

Technical Indicators

Market Signals
Indicator
RNTX
OPAD
Relative Strength Index (RSI) 69.15 64.94
Support Level $1.08 $0.71
Resistance Level $2.18 $0.90
Average True Range (ATR) 0.19 0.07
MACD 0.04 0.03
Stochastic Oscillator 83.78 96.91

Price Performance

Historical Comparison
RNTX
OPAD

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About OPAD Offerpad Solutions Inc.

Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.

Share on Social Networks: